Since 2010, three new blood thinners, Xarelto, Pradaxa and Eliquis, have battled it out for supremacy in the fast-growing novel oral anticoagulant market.
And while Pradaxa was the first to gain FDA approval, Xarelto has reigned as the market leader for years with around twice as many prescriptions as its nearest competitor.
For the second time in the past year, the US Food and Drug Administration has warned consumers that two popular diabetes medications, Invokana and Farxiga, may be linked to serious side effects.
First, the agency warned of potentially fatal blood acid levels from the drugs in May of 2015, which was followed by required warning label changes in December to address both this and the potential for urinary tract infections.
A popular type of over-the-counter heartburn drug taken by millions of people around the world may raise the likelihood of heart attacks, dementia and kidney problems, according to a new study.
The research, published last month, concerns proton pump inhibitors, or PPIs, which are sold under brand names like Nexium. These are not to be confused with other types of heartburn meds called H2 blockers, which are sold under brand names like Zantac.
Doctors from Harvard Medical School and Brigham and Women’s Hospital released a new study last week further questioning the safety of blood thinning drugs like Pradaxa, based on the risks of internal bleeding.
The study comes as the maker of the drug, German pharmaceutical giant Boehringer Ingelheim, prepares to defend thousands more lawsuits from injured patients and their families after paying out an initial $650 million settlement in 2014.
The FDA this month issued a warning to patients taking the antipsychotic drug Zyprexa, advising that they may be at a higher risk for a severe skin condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
The warning was issued after the agency compiled a higher-than-expected number of reports of patients suffering the potentially deadly condition.
The Food and Drug Administration recently added a strong warning to the yeast infection drug Diflucan for women who are pregnant, saying that even small doses have been associated with a higher risk of miscarriage.
Diflucan, taken orally, was approved by the FDA in 1990 and is sold by Pfizer. It is prescribed for a variety of fungal infections in the lungs, bladder, esophagus, mouth and blood, and is also indicated to fight infections in those with cancer or weakened immune systems. But it is used most often for vaginal yeast infections.
A jury in St. Louis, Missouri yesterday handed Johnson & Johnson its third loss in a growing number of lawsuits alleging the company’s baby powder products caused deadly ovarian cancer in users.
And, although this case didn’t reach the historic $72 million level awarded to the family of Jacqueline Fox in February, it’s still staggering as the jury ordered J&J to pay a whopping $55 million to a victim whose cancer has gone into remission.
The U.S. Food and Drug Administration took the unusual step this week of withdrawing its approval of four medications used to treat high cholesterol, based on studies that show the benefits of the drugs no longer outweighed the risks.
The change will affect drugs containing niacin, also known as vitamin B-3, and/or fenofibric acid, when the medications are combined with statins.
Just weeks after a St. Louis jury ordered Johnson & Johnson to pay $72 million to the family of a woman who died of ovarian cancer after years of using the company’s baby powder products, the second baby powder trial in the Missouri court has started.
This week, the trial began in a lawsuit filed by Gloria Ristesund, a woman diagnosed with ovarian cancer after using Johnson & Johnson’s talcum powder products for 40 years.
Two popular type-2 diabetes drugs are in the news after the FDA warned this week that patients taking them may face higher risks of heart failure.
The new warning, issued Tuesday, focuses on the DPP-4 inhibitors Onglyza (saxagliptin), sold by AstraZeneca, and Nesina (alogliptin), sold by Takeda. Together, these drugs are prescribed more than 3 million times each year.
A federal judge this week issued a ruling that pharmaceutical giant Bayer will have to face many of the growing lawsuits alleging its permanent birth control implant Essure caused serious patient side effects.
The decision comes in the wake of other significant Essure news: a recent study showed the FDA had underestimated the number of fetal deaths linked to the devices; and the FDA’s response of ordering new Essure clinical trials and a black box Essure warning label.
This past fall, news broke that a study published in the New England Journal of Medicine comparing the safety and effectiveness of Xarelto and warfarin may be tainted due to a faulty measuring device and missing data.
Now, questions are arising about whether the makers of Xarelto, Bayer and Johnson & Johnson, were complicit in keeping the data from the journal’s editors.